Qingdao Haier Biomedical Co Ltd (688139) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) has a cash flow conversion efficiency ratio of 0.002x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥7.33 Million ≈ $1.07 Million USD) by net assets (CN¥4.34 Billion ≈ $634.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Qingdao Haier Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Qingdao Haier Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Qingdao Haier Biomedical Co Ltd (688139) financial obligations for a breakdown of total debt and financial obligations.
Qingdao Haier Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qingdao Haier Biomedical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wüstenrot & Württembergische AG
XETRA:WUW
|
0.130x |
|
Ruentex Industries Ltd
TW:2915
|
-0.001x |
|
Concentrix Corporation
NASDAQ:CNXC
|
-0.030x |
|
Anhui Hengyuan Coal Industry and Electricity Power Co Ltd
SHG:600971
|
0.052x |
|
Sansure Biotech Inc
SHG:688289
|
0.008x |
|
Mirae Asset Life Insurance Co Ltd
KO:085620
|
0.219x |
|
Jinzhou Jixiang Molybdenum Co Ltd
SHG:603399
|
-0.010x |
|
Telecom Argentina SA ADR
NYSE:TEO
|
0.093x |
Annual Cash Flow Conversion Efficiency for Qingdao Haier Biomedical Co Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Qingdao Haier Biomedical Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688139 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.62 Billion ≈ $676.52 Million |
CN¥267.89 Million ≈ $39.20 Million |
0.058x | -8.25% |
| 2024-12-31 | CN¥4.62 Billion ≈ $675.78 Million |
CN¥291.67 Million ≈ $42.68 Million |
0.063x | +12.50% |
| 2023-12-31 | CN¥4.44 Billion ≈ $649.71 Million |
CN¥249.26 Million ≈ $36.48 Million |
0.056x | -63.17% |
| 2022-12-31 | CN¥4.15 Billion ≈ $607.03 Million |
CN¥632.43 Million ≈ $92.54 Million |
0.152x | -12.28% |
| 2021-12-31 | CN¥3.64 Billion ≈ $532.46 Million |
CN¥632.43 Million ≈ $92.54 Million |
0.174x | -30.53% |
| 2020-12-31 | CN¥2.78 Billion ≈ $407.46 Million |
CN¥696.62 Million ≈ $101.94 Million |
0.250x | +119.32% |
| 2019-12-31 | CN¥2.46 Billion ≈ $359.82 Million |
CN¥280.49 Million ≈ $41.04 Million |
0.114x | -14.74% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.98 Million |
CN¥149.00 Million ≈ $21.80 Million |
0.134x | -44.55% |
| 2017-12-31 | CN¥614.76 Million ≈ $89.96 Million |
CN¥148.32 Million ≈ $21.70 Million |
0.241x | -20.99% |
| 2016-12-31 | CN¥722.81 Million ≈ $105.77 Million |
CN¥220.72 Million ≈ $32.30 Million |
0.305x | -- |
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard … Read more